Table 6. Impact of BRCA1/2 P/LP variants on the DFS of breast cancer patients from subgroups of N0 and N1~3.
| P/LP variants | #Cases (events) | HR (95% CI) a | P a | Adjusted HR (95% CI) b | P b |
|---|---|---|---|---|---|
| N0 | |||||
| Germline and somatic combined variants | |||||
| Non-carrier | 165 (9) | 1 | 1 | ||
| BRCA1 | 11 (2) | 4.08 (0.86–19.4) | 0.08 | 1.7 (0.28–10.32) | 0.56 |
| BRCA2 | 12 (0) | 0 | 0.98 | 0 | 0.99 |
| Germline variants | |||||
| Non-carrier | 165 (9) | 1 | 1 | ||
| BRCA1 | 9 (2) | 5.4 (1.12–26.0) | 0.04 | 3.62 (0.47–27.63) | 0.21 |
| BRCA2 | 10 (0) | 0 | 0.99 | 0 | 0.99 |
| Somatic variants | |||||
| Non-carrier | 165 (9) | 1 | 1 | ||
| BRCA1/2 | 4 (0) | 0 | 0.70 | 0 | 0.99 |
| N1~N3 | |||||
| Germline and somatic combined variants | |||||
| Non-carrier | 215 (26) | 1 | 1 | ||
| BRCA1 | 8 (1) | 1.01 (0.14–7.47) | 0.99 | 0.7 (0.08–6.02) | 0.74 |
| BRCA2 | 15 (0) | 0 | 0.98 | 0 | 0.98 |
a Univariate Cox proportional hazards regression models
b Multivariate Cox proportional hazards regression models. HR was adjusted by age at diagnosis, molecular subtype (Luminal A, Luminal B, TNBC, HER2+ and ER-PR+), tumor grade (grade I/II and III) and administration of standard therapy.